LOU064A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $391,589 | 29 | 0 |
| 2019 | $143,491 | 30 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $535,079 | 59 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED PHASE 2B DOSE-FINDING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF LOU064 IN ADULT CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO ARE INADEQUATELY CONTROLLED BY SECOND GENERATION H1 | Novartis Pharmaceuticals Corporation | $397,189 | 0 |
| AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LOU064 IN ELIGIBLE SUBJECTS WITH CSU WHO HAVE PARTICIPATED IN PRECEDING STUDIES WITH LOU064 | Novartis Pharmaceuticals Corporation | $137,890 | 0 |
Top Doctors Receiving Payments for LOU064A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Owensboro, KY | $535,079 | 59 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $535,079
Product Information
- Type Drug
- Total Payments $535,079
- Total Doctors 0
- Transactions 59
About LOU064A
LOU064A is a drug associated with $535,079 in payments to 0 healthcare providers, recorded across 59 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $391,589 was paid across 29 transactions to 0 doctors.
The most common payment nature for LOU064A is "Unspecified" ($535,079, 100.0% of total).
LOU064A is associated with 2 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED PHASE 2B DOSE-FINDING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF LOU064 IN ADULT CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO ARE INADEQUATELY CONTROLLED BY SECOND GENERATION H1" ($397,189).